Cafeína a 5% e em nanocápsulas no tratamento dermatofuncional para fibroedemagelóide: ensaio clínico randomizado cego

Abstract

Introduction: Fibroedemageloid (EGF) is a condition in which there is edematous infiltration of subcutaneous connective tissue and presents as depressions in the skin. Objective: To compare the effects of 5% caffeine and nanocapsules for the treatment of grade II and III EGF. Methods: This was a blind randomized clinical trial conducted from February to September 2019, approved under no. 3,212,737. A total of 26 women were randomized into 2 groups: group 1 was given 5% caffeine in the right gluteus region (D) and group 2 was given nanocapsulated caffeine and in both groups the common gel was applied to the gluteus. And, through Therapeutic Ultrasound (US) and Aussie Current (AC) Combination Therapy, in three-dimensional continuous mode Sonophoresis, for ten minutes, with US intensity of 1.5 watts / cm², carrier frequency of 4Khz, modulated frequency of 10Hz , for ten calls twice a week. Results: There was a reduction in the number of gluteus D depressions in group 1 and 2 with p <0.001, an improvement in the gluteus D depression depth in both groups (p <0.001) and a reduction in the severity of the EGF. Conclusion: The use of 5% caffeine and nanocapsulated caffeine by combined US and CA therapy provides improvement in the appearance of grade II and III EGF.